Marizyme transfers all assets via assignment for benefit of creditors; files under Florida Chapter 727

MARIZYME, INC.

Company entered Assignment for Benefit of Creditors on April 14, 2026, transferring all assets to Assignee Peter Hurwitz.
Company is unable to pay debts as they become due; intends to file under Florida Chapter 727 by April 17, 2026.
Assignee will liquidate assets and distribute proceeds to creditors pro rata in accordance with Florida Statutes § 727.114.
Board determined transfer of all or substantially all assets was in best interests; CEO David Barthel authorized the agreement.

item 1.01 item 1.03 item 2.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-017470
form_type: 8-K
ticker: null
cik: 0001413754
company_name: MARIZYME, INC.
filed_at: 2026-04-17T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.255061+00:00
generated_at: 2026-05-15T05:29:08.921507+00:00
sec_items: ["1.01", "1.03", "2.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 1.0
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-017470
json_url: https://secwatch.observer/filing/0001493152-26-017470.json
markdown_url: https://secwatch.observer/filing/0001493152-26-017470.md
text_url: https://secwatch.observer/filing/0001493152-26-017470.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1413754/000149315226017470/0001493152-26-017470-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1413754/000149315226017470/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-017470

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.